Michael King - Oct 30, 2023 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Michael G. King, Jr.
Stock symbol: SABS
Transactions as of: Oct 30, 2023
Transactions value $: $0
Form type: 4
Date filed: 11/3/2023, 04:50 PM
Next filing: Nov 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SABS	Employee Stock Option (right to buy)	Award	$0	+850K		$0.00	850K	Oct 30, 2023	Common Stock	850K	$0.80	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023.
F2	The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (October 30, 2024), and the remainder vesting thereafter in equal monthly installments over a three year period.

Content

Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023.

The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (October 30, 2024), and the remainder vesting thereafter in equal monthly installments over a three year period.